# Moolec Science SA > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Moolec Science SA). ## Overview Moolec Science SA is a U.S.-based food technology company that engineers plants and microbes to produce proteins, lipids, enzymes, and other biomolecules for the food and agriculture value chain. Its platform combines molecular farming and precision fermentation, with operations and development activities spanning the United States, Europe, and South America. ## Products & services • Molecular farming crops for protein and lipid production • Precision fermentation for target proteins and enzymes • Alternative protein ingredients for food applications • Nutritional oils and bioactive compounds • Biological inputs for regenerative agriculture - **Molecular farming ingredients** (30%) — Proteins and lipids produced in crops such as soy and safflower. - **Precision fermentation products** (30%) — Microbially produced proteins, enzymes, and other biomolecules. - **Alternative protein solutions** (20%) — Functional ingredients designed for food formulation and nutrition. - **Nutritional oils and bioactive compounds** (10%) — Specialty biomolecules and oils for food and ingredient applications. - **Agriculture biological inputs** (10%) — Biological products intended to support regenerative agriculture. - Molecular farming crops for protein and lipid production - Precision fermentation for target proteins and enzymes - Alternative protein ingredients for food applications - Nutritional oils and bioactive compounds - Biological inputs for regenerative agriculture ## Customers Moolec’s customers are food companies and ingredient buyers that need scalable sources of protein, lipids, and functional biomolecules. Its products are aimed at commercial ingredient channels where functionality, nutrition, and cost structure matter more than simple commodity volume. - **Food and beverage manufacturers** (primary) — Buy protein and lipid ingredients for formulation, nutrition, and functionality. - **Ingredient companies** (primary) — Source biomolecules and processing inputs for downstream food applications. - **Agriculture and regenerative farming customers** (secondary) — Use biological inputs and crop-based technologies for farming applications. - **Industrial biotechnology partners** (secondary) — Work with fermentation-based outputs such as enzymes and target proteins. - Food companies seeking alternative protein ingredients - Ingredient manufacturers needing functional biomolecules - Customers wanting animal-like functionality from plant systems - Commercial buyers of enzymes and specialty fermentation outputs - Agriculture users seeking biological inputs for regenerative farming ## Geography Moolec describes operations across the United States, Europe, and South America, with a precision fermentation facility in Finland under the SynBio Powerlabs brand. The geographic footprint matters because the company combines crop-based development, industrial fermentation, and regulatory validation across multiple regions. - **United States** (33%) — Reported as part of the company's operating footprint. - **Europe** (33%) — Finland is specifically named for precision fermentation operations. - **South America** (34%) — Reported as part of the company's operating footprint. - Operations span the United States, Europe, and South America - Finland is a key development location for precision fermentation - Crop programs rely on agricultural environments for validation - Cross-border operations support R&D, manufacturing, and regulatory work ## Strategy Moolec’s strategy is to combine molecular farming and precision fermentation so it can develop ingredients through two complementary production pathways. The company is building an integrated platform from molecular design to validation and commercial channel development, with the goal of improving scalability, shortening time to market, and supporting product functionality. - **Integrate molecular farming and precision fermentation** (short-term) — Two production routes can diversify technical risk and broaden ingredient capabilities. - **Scale manufacturing and regulatory readiness** (medium-term) — Commercial ingredients require validated production and market access before adoption. - **Build commercial relationships with food companies** (medium-term) — Downstream customer adoption is needed to convert technology into ingredient sales. - Combine crop-based and fermentation-based production pathways - Use agricultural scalability to anchor long-term cost structure - Advance a Finland fermentation facility for commercial scale-up - Build a seed-to-ingredient platform across design and validation - Develop commercial channels with food companies ## Risks Moolec’s main risks come from developing novel biological platforms that must scale technically, pass regulatory scrutiny, and achieve commercial acceptance. The business is also exposed to multi-region execution risk because its crop, fermentation, and validation activities span the United States, Europe, and South America. - **Technology and scale-up failure** [high] — Novel proteins and biomolecules must work at industrial scale, not just in the lab. - **Regulatory and food safety approval delays** [high] — Alternative proteins and engineered biomolecules may require extensive validation. - **Commercial adoption uncertainty** [high] — Customers may take time to qualify new ingredients and switch from incumbents. - **Cross-border operating complexity** [medium] — R&D, manufacturing, and regulatory work across multiple regions can raise execution risk. - **Intellectual property challenges** [medium] — The model depends on patented platforms and enforceable know-how. - Technology scale-up risk across crops and fermentation systems - Regulatory approval risk for novel food ingredients and biomolecules - Customer adoption risk if functionality or cost targets are not met - Cross-border execution risk across the U.S., Europe, and South America - IP protection risk despite a large patent portfolio ## Accounting Moolec’s accounting is shaped by business combinations, intangible assets, leased assets, and estimates tied to a developing platform. The company also has to account for discontinued operations and subsidiary control changes, which can materially affect comparability across periods. IFRS 3 reverse acquisition accounting and IFRS 18 transition are important because they influence presentation, consolidation, and how results are interpreted. - **IFRS 3 reverse acquisition** — Impacts comparability of reported financial statements across periods. - **Intangible asset amortization** — Affects operating expense and asset carrying values. - **Lease accounting** — Affects balance sheet leverage and expense recognition. - **Discontinued operations** — Can make underlying performance harder to compare. - **IFRS 18 presentation** — Changes how investors read operating performance. - Reverse acquisition accounting affects consolidation basis and comparability - Intangible asset amortization can materially affect reported results - Lease accounting matters for the Finland fermentation facility and other sites - Discontinued operations can distort year-over-year trend analysis - Estimates and judgments are important in early-stage biotech assets --- *Last updated: 2026-09-28T12:13:18.600057+00:00*